Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EPS (Weighted Average and Diluted) (2016 - 2025)

Guided Therapeutics' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at -$0.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 50.0% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.04, a 20.0% increase, with the full-year FY2025 number at -$0.04, up 20.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Guided Therapeutics, roughly flat from -$0.01 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for GTHP hit a ceiling of -$0.0 in Q3 2021 and a floor of -$0.09 in Q2 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.02 across 5 years, with a median of -$0.02 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 84.21% in 2021 and later crashed 689.24% in 2022.
  • Tracing GTHP's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.04 in 2021, then decreased by 0.0% to -$0.04 in 2022, then surged by 77.07% to -$0.01 in 2023, then tumbled by 118.04% to -$0.02 in 2024, then soared by 50.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GTHP at -$0.01 in Q4 2025, -$0.01 in Q3 2025, and -$0.01 in Q2 2025.